MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2025)
MeiraGTx Holdings (MGTX) posted Net Income towards Common Stockholders of $15.1 million for Q4 2025, up 129.87% on a QoQ basis from -$50.5 million in Q3 2025, and up 138.3% year-over-year from $6.3 million in Q4 2024.
MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends
MeiraGTx Holdings' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $15.1 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 138.3% year-over-year to $15.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$114.2 million (up 22.73% YoY) and the FY2025 annual result came in at -$114.2 million, up 22.73% from the prior year.
- Net Income towards Common Stockholders was $15.1 million for Q4 2025 at MeiraGTx Holdings, up from -$50.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $20.2 million in Q4 2023 and bottomed at -$50.5 million in Q3 2025.
- A 5-year average of -$27.8 million and a median of -$30.7 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 303.37% — and 2023, when it jumped 174.01%.
- MeiraGTx Holdings' Net Income towards Common Stockholders stood at -$9.9 million in 2021, then slumped by 175.55% to -$27.3 million in 2022, then soared by 174.01% to $20.2 million in 2023, then plunged by 294.9% to -$39.4 million in 2024, then jumped by 138.3% to $15.1 million in 2025.
- Business Quant data shows MGTX's Net Income towards Common Stockholders at $15.1 million in Q4 2025, -$50.5 million in Q3 2025, and -$38.8 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | -0.68 |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 205.99 Mn |
| 10 | MeiraGTx Holdings | 1.00 Bn | 935.42 Mn | - | 15.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.09 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Jun 30, 2025 | -38.80 Mn |
| Mar 31, 2025 | -39.98 Mn |
| Dec 31, 2024 | -39.40 Mn |
| Sep 30, 2024 | -39.33 Mn |
| Jun 30, 2024 | -48.62 Mn |
| Mar 31, 2024 | -20.44 Mn |
| Dec 31, 2023 | 20.22 Mn |
| Sep 30, 2023 | -44.30 Mn |
| Jun 30, 2023 | -29.58 Mn |
| Mar 31, 2023 | -30.36 Mn |
| Dec 31, 2022 | -27.31 Mn |
| Sep 30, 2022 | -37.28 Mn |
| Jun 30, 2022 | -33.97 Mn |
| Mar 31, 2022 | -31.05 Mn |
| Dec 31, 2021 | -9.91 Mn |
| Sep 30, 2021 | -25.95 Mn |
| Jun 30, 2021 | -20.09 Mn |
| Mar 31, 2021 | -23.62 Mn |